» Articles » PMID: 34784562

Predictors of Outcomes Following Liver Transplant in Hepatopulmonary Syndrome: An OPTN Database Analysis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2021 Nov 16
PMID 34784562
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatopulmonary syndrome (HPS) is a type of pulmonary vascular disease occurring exclusively in those with underlying liver disease, associated with significant mortality in patients awaiting liver transplantation (LT). LT is curative in HPS, and these patients are granted Model for End Stage Liver Disease (MELD) exception points to expedite LT. The purpose of this study is to use multivariable competing risk Accelerated Failure Time models and propensity matching to examine the relationship between pre-LT hypoxemia and post-LT outcomes in HPS. We performed a retrospective cohort study of UNOS/OPTN database of all adult patients undergoing LT between January 1, 2006 and January 12, 2020. Pre-LT PaO was significantly associated with post-LT mortality in HPS, with each 1 mmHg increase in PaO significantly decreasing the risk of post-LT mortality (coefficient 0.039, HR = 0.95, p = 0.001). HPS patients with a pre-LT PaO < 54 mmHg demonstrated increased mortality following LT as compared to matched non-HPS cirrhotic patients. We conclude that HPS patients with a PaO, 54 mmHg are at increased risk of post-LT mortality and may identify high-risk patients who would benefit from additional resources during LT, and that the effects of HPS MELD exception points to optimize post-LT outcomes should be continuously re-evaluated.

Citing Articles

Unmasking Hypoxia in Cirrhosis Patients: Six-Minute Walk Test as a Screening Tool for Hepatopulmonary Syndrome.

Singhai A, Mallik M, Jain P Adv Biomed Res. 2022; 11:50.

PMID: 35982866 PMC: 9379911. DOI: 10.4103/abr.abr_150_21.

References
1.
Pascasio J, Grilo I, Lopez-Pardo F, Ortega-Ruiz F, Tirado J, Sousa J . Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant. 2014; 14(6):1391-9. DOI: 10.1111/ajt.12713. View

2.
Porres-Aguilar M, Altamirano J, Torre-Delgadillo A, Charlton M, Duarte-Rojo A . Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur Respir Rev. 2012; 21(125):223-33. PMC: 9487331. DOI: 10.1183/09059180.00007211. View

3.
Kish T, Aziz A, Sorio M . Hepatitis C in a New Era: A Review of Current Therapies. P T. 2017; 42(5):316-329. PMC: 5398625. View

4.
Krowka M, Fallon M, Kawut S, Fuhrmann V, Heimbach J, Ramsay M . International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016; 100(7):1440-52. DOI: 10.1097/TP.0000000000001229. View

5.
Krowka M . Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease. Clin Liver Dis (Hoboken). 2020; 15(Suppl 1):S13-S24. PMC: 7050952. DOI: 10.1002/cld.846. View